Nonalcoholic steatohepatitis (NASH) prevalence is rising with no pharmacotherapy approved. A major hurdle in NASH drug development is the poor translatability of preclinical studies to safe/effective clinical outcomes, and recent failures highlight a need to identify new targetable pathways. Dysr...
iTRAQ-based proteomics was performed to explore the mechanism underlying Florfenicol-induced stem cell toxicity and assess the overall protein changes in P19SCs post FLO treatment.
